Urokinase-Derived Peptide A6

Product overview
Catalog Number
PPH08-1031
Sequence
Ac-Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu-NH2
Target
CD44 Inhibitor; Anti-Tumor Properties, Sequence derived from peptide domain of human urokinase plasminogen activator (uPA). It is able to bind to and inhibit CD44 activity that contributes to tumorgenesis.
Description
An octapeptide (amino acids 136-143) derived from the proteolytic enzyme urokinase plasminogen activator (uPA), with potential antineoplastic activity. A6 is derived from the nonreceptor-binding domain and connecting region of urokinase. Administration of A6 inhibits the interaction of uPA with its receptor uPAR, and may inhibit endothelial cell motility and tumor cell invasion. uPA and uPAR promote extracellular matrix degradation and growth factor activation and correlate positively with angiogenesis, cancer cell invasion and metastasis. Sequence derived from peptide domain of human urokinase plasminogen activator (uPA). It is able to bind to and inhibit CD44 activity that contributes to tumorgenesis. Ac-KPSSPPEE-NH2. (Trifluoroacetate Salt) (M.W. 910.99) C39H62N10O15 CD44 Inhibitor; Anti-Tumor Properties
Category
Catalog peptides, Biologically Active Peptides
Product Properties
Quantity

1mg, 5mg
Storage

Shipped at 4°C. Store at -20°C for one year.
Purity

> 95%
Source

Synthetic
Forma appearance

Lyophilized powder
  • For research use only
  • Not for use in diagnostic procedures

€20,00 – €140,00 Tax excluded
Contact us to request price here
Register to buy peptides
Contact us